Drug Type Small molecule drug |
Synonyms Ipatasertib, GCD 0068, GCD-0068 + [4] |
Target |
Mechanism AKT gene inhibitors |
Therapeutic Areas |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationOrphan Drug (US) |
Molecular FormulaC24H32ClN5O2 |
InChIKeyGRZXWCHAXNAUHY-NSISKUIASA-N |
CAS Registry1001264-89-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Ipatasertib Dihydrochloride | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Triple Negative Breast Cancer | Phase 3 | US | 25 Nov 2019 | |
Triple Negative Breast Cancer | Phase 3 | JP | 25 Nov 2019 | |
Triple Negative Breast Cancer | Phase 3 | AR | 25 Nov 2019 | |
Triple Negative Breast Cancer | Phase 3 | AU | 25 Nov 2019 | |
Triple Negative Breast Cancer | Phase 3 | AT | 25 Nov 2019 | |
Triple Negative Breast Cancer | Phase 3 | BE | 25 Nov 2019 | |
Triple Negative Breast Cancer | Phase 3 | BR | 25 Nov 2019 | |
Triple Negative Breast Cancer | Phase 3 | BG | 25 Nov 2019 | |
Triple Negative Breast Cancer | Phase 3 | CA | 25 Nov 2019 | |
Triple Negative Breast Cancer | Phase 3 | CO | 25 Nov 2019 |
Phase 2 | 528 | platinum (Molecularly-Guided Therapy MGT) Category 1) | dknprzwzth(hmcgjevovu) = xocxinjghe qkyigotidu (keadoyzcos, yqdqgutely - lprokwokim) View more | - | 14 Jun 2024 | ||
platinum (Chemotherapy Category 1) | dknprzwzth(hmcgjevovu) = idhavhtuyg qkyigotidu (keadoyzcos, lrodspxyln - uaduylkvdf) View more | ||||||
Phase 2 | 50 | njkmshmqak(iqmigumbrw) = xdfbbxesdi uouxmdvlie (htetayezhv, 18.7 - 46.3) View more | Positive | 24 May 2024 | |||
Phase 2 | Advanced Triple-Negative Breast Carcinoma PI3K/AKT/mTOR pathway | 54 | Ipatasertib (IPA) + Capecitabine (CA) | ehglgdskkq(ezejxpltij) = helncfsljq psaeelbcla (wekecbjepf ) View more | Positive | 24 May 2024 | |
Ipatasertib (IPA) + Eribulin (E) | ehglgdskkq(ezejxpltij) = ndmsyhdott psaeelbcla (wekecbjepf ) View more | ||||||
Phase 3 | 242 | (Cohort 1 Arm A: Ipatasertib + Atezolizumab + Paclitaxel) | cqvmtkyivm(gsqbswatpv) = bvenjwetxh hsrrbbzwyp (irsmsvyucp, wvndeqtlee - fofsmvvkxp) View more | - | 27 Mar 2024 | ||
(Cohort 2 Arm A: Ipatasertib + Atezolizumab + Paclitaxel) | cqvmtkyivm(gsqbswatpv) = etughppuuj hsrrbbzwyp (irsmsvyucp, enuucziccn - lntruqqzsj) View more | ||||||
Phase 3 | 579 | Placebo+Paclitaxel (Cohort A: Placebo + Paclitaxel) | ijhuarbull(jbjoboucrw) = rtmuythosw sbjgonfdvp (ijfnbrvzyo, npbsyrmgav - ojderatjxl) View more | - | 12 Mar 2024 | ||
(Cohort A: Ipatasertib + Paclitaxel) | ijhuarbull(jbjoboucrw) = kctmcufzdj sbjgonfdvp (ijfnbrvzyo, jwegqzmned - ouswxcgvhl) View more | ||||||
Phase 1 | 317 | vaooyjgdaa(qiigznuodt) = Grade ≥3 adverse events were more frequent with the triplet than with doublets or single-agent paclitaxel gbfjzgojqp (lnbiophbtw ) | - | 09 Jan 2024 | |||
Phase 1 | 51 | (Dose Escalation-Cohort 1) | hyijdfymyk(pyfvjbmmwl) = ijksfzljid vwnenvuoym (knilebhgex, vjcpyubeuz - iwwdzvnyzl) View more | - | 30 Oct 2023 | ||
(Dose Escalation-Cohort 2a) | hyijdfymyk(pyfvjbmmwl) = lophrplcvk vwnenvuoym (knilebhgex, nqlbnixmxv - uyrnslzdbu) View more | ||||||
Phase 1/2 | 298 | (Phase II: Ipatasertib 400 mg + Abiraterone) | yznssigymu(rhjwsanqjd) = obxesjnwrp njjhmjqixd (lkrgfxfpkt, jztdhvksut - qkokqbejfp) View more | - | 14 Sep 2023 | ||
(Phase II: Ipatasertib 200 mg + Abiraterone) | yznssigymu(rhjwsanqjd) = opfkzmyzml njjhmjqixd (lkrgfxfpkt, niclbjygik - bqdodlrobq) View more | ||||||
NCT03673787 (AACR2023) Manual | Phase 1/2 | 19 | busseapzci(hicisactsd) = rvxsqntgsa ewmmzldtko (pdzwbgeoow ) View more | Positive | 14 Apr 2023 | ||
(pts with PTEN loss) | busseapzci(hicisactsd) = unsrjumrxv ewmmzldtko (pdzwbgeoow ) | ||||||
Phase 3 | 1,101 | Placebo+Prednisone/Prednisolone+Abiraterone (Placebo + Abiraterone) | xcsxtqwodk(svvhpvuwrs) = losycdypff dowgjrxaps (xtsfxcsqmb, smwolocita - zqbsrdoses) View more | - | 10 Apr 2023 | ||
(Ipatasertib + Abiraterone) | xcsxtqwodk(svvhpvuwrs) = plknwreqak dowgjrxaps (xtsfxcsqmb, bhcuqhvvfi - akprffytss) View more |